期刊文献+

DNA拓扑异构酶在人体组织的分布及其与肿瘤的关系 被引量:2

THE DISTRIBUTION OF TOPOISOMERASES ACTIVITIES IN NOMAL HUMAN TISSUES AND THE CORRELATION WITH THOSE IN TUMOR TISSUES
暂未订购
导出
摘要 作者检测了人体多种组织器官及相应肿瘤组织的拓扑酶Ⅰ及Ⅱ的活力,结果表明,除睾丸组织拓扑酶Ⅰ和Ⅱ活力显著高于其它组织外,其余各组织拓扑酶Ⅰ和Ⅱ的活力水平基本一致;肿瘤组织与非肿瘤组织拓扑酶Ⅰ活力无明显差异;恶性肿瘤组织的拓扑酶Ⅱ活力较良性肿瘤及非肿瘤组织明显升高。 DNA toposicmerases have been found to have an important role in genetic events. In order to explore the biological function of the enzymes, authors studied the distribution and specific activities of DNA topoisomerases in some organs of the human body and their malignant tissues; and discovered that the activities of DNA topoisomerase Ⅰ and Ⅱ existed in all of human organs and their malignant tissues including liver, lungs, kidney, stomach, brain, bladder, thyroid, prostate, testicle. There was no significant difference of the activities of DNA toposiomerase Ⅰ between normal tissues and malignant tissues except testicle in which the activities of DNA topoisomerase Ⅰ and Ⅱ were higher than those of other tissues. The specific activities of DNA topoisomerase I were much higher in malignant tissues than those in normal tissues.
出处 《中山医科大学学报》 CSCD 1992年第2期45-48,共4页 Academic Journal of Sun Yat-sen University of Medical Sciences
关键词 DNA 拓扑异构酶 人体组织 肿瘤 DNA topoisomerase Ⅰ and Ⅱ human tissues cell proliferation neoplasms
  • 相关文献

参考文献5

  • 1张穗生,生物化学杂志,1988年,4卷,4期,324页
  • 2王理开,中山医科大学学报,1987年,8卷,2期,40页
  • 3Wang J C,Ann Rev Biochem,1985年,54卷,665页
  • 4Liu L F,1983年
  • 5Liu L F,Nucleic Acids Res,1981年,9卷,3979页

同被引文献22

  • 1赵永同,朱峰.凋亡的分子机理[J].生命科学,1996,8(2):19-23. 被引量:24
  • 2张文卿.拓扑异构酶Ⅱ和肿瘤多药耐药[J].中国肿瘤临床,1996,23(3):208-212. 被引量:16
  • 3Wang JC.DNA topoisomcrasea[J].Annu Rev Biochem,1996,65:635.
  • 4Nitiss JL.Investigating the biological functions of DNA topoisomeraes in eukaryotic cells[J].Bioehim Biophys Acta,1998,1400(123):63-68.
  • 5Tanoguchi K,Sasano H,Yabuki N,et al.Immunohistoehemical and two parameter flow cytometric studies of DNA topoisomerase Ⅱ alpha in human epithelial ovarian carcinoma and gern cell tumor[J].Mod Pathol,1998;11(2):186-193.
  • 6Gotlieb WH,Goldberg,Weisz B,et al.Topoisomerasell immunostaining as a prognostic marker for survival in ovrarian cancer[J].Gynecol Oncol.2001,82(1):99-104.
  • 7Kigawa J,Takahashi M,Minagawa Y.et al.Topoisomerase activity and reoponse to second-line chemotherapy consisting of camptothecin-11 and eisplatin in patients with ovarian cancer[J].Int J Cancer,1999,84(5):521-524.
  • 8Kluza L,Lansiaux A,Wattcz N,et al.Apoptotie response of HL260 humanleukemia cells to the anti-tumor drug TAS2103[J].Cancer Res,2000,15:40-77.
  • 9Vikhanskaya F,Clerico L,Valenti M,et al.Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin:possible role of p53[J].Int J Cancer,1997,72(1):155-168.
  • 10Fedier A,Steiner RA,Schwam VA,et al.The effet of loss of Brcal on the sensitivity to anticancer agents in p53-deficient cells[J].Int J Oncol,2003,22(5):1169-1173.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部